Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.77USD
12 Dec 2017
Change (% chg)

$-0.27 (-4.47%)
Prev Close
$6.04
Open
$6.07
Day's High
$6.13
Day's Low
$5.76
Volume
19,136
Avg. Vol
24,835
52-wk High
$11.26
52-wk Low
$4.03

Latest Key Developments (Source: Significant Developments)

Foamix Q2 loss per share $0.27
Wednesday, 10 Aug 2016 

Foamix Pharmaceuticals Ltd : Q2 loss per share $0.27 . Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Foamix reports second quarter 2016 financial results and provides business update .Q2 revenue $752,000 versus $109,000.  Full Article

Foamix names Dr Stanley Hirsch chairman, and Dr Dalia Megiddo member of board
Monday, 16 May 2016 

Foamix Pharmaceuticals Ltd : Hirsch replaces meir eini, who is retiring from board but will continue as co's chief innovation officer .Foamix names dr. Stanley hirsch as chairman, and dr. Dalia megiddo as a member of the board of foamix pharmaceuticals.  Full Article

Foamix reports Q1 loss per share $0.15
Tuesday, 10 May 2016 

Foamix Pharmaceuticals Ltd : Foamix reports first quarter 2016 financial results and provides business update . Q1 loss per share $0.15 .Q1 revenue $745,000 versus $448,000.  Full Article

Foamix Ltd announces positive results from phase 1 study to characterize minocycline bioavailability of Fmx-101 compared to solodyn
Thursday, 7 Jan 2016 

Foamix Ltd:Announced positive results from a Phase 1 maximum use pharmacokinetics study of FMX-101 (a topical foam containing 4% minocycline), which is in development for the treatment of moderate-to-severe acne.Says FMX-101 was well-tolerated.  Full Article

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update